4-Methylsulfonyl-Substituted Piperidine Urea Compounds
AssigneeMyoKardia, Inc.
InventorsJohan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Life of this patent
Estimating the term…
Abstract
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
Claims21
1-35. (canceled)
A method for preparing a compound of formula xi:
- or a pharmaceutically acceptable salt thereof,
- the method comprising:
- reacting a compound of formula ix
- or a salt thereof,
- with a compound of formula x
- to produce the compound of formula xi, wherein:
- Ar is aryl;
- Ar1 is a 5- to 6-membered heteroaryl having at least one nitrogen atom ring member, and is optionally substituted with from 1-3 Ra;
- Ar2 is a 5- to 10-membered aryl or heteroaryl, which is optionally substituted with from 1-5 Rb;
- R1 and R2 are each independently a member selected from H, F, C1-C4 alkyl, C1-C4 deuteroalkyl, and C1-C4 haloalkyl;
- or optionally R1 and R2 can be combined to form a C3-C5 carbocyclic ring which is optionally substituted with one or two F;
- each Ra is independently selected from the group consisting of halo, CN, hydroxyl, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, —CORa1, —CO2Ra1, —SO2Ra1, —SO2NRa1Ra2, and —CONRa1Ra2, wherein each Ra1 and Ra2 is independently selected from the group consisting of H and C1-C4 alkyl or optionally Ra1 and Ra2 when attached to a nitrogen atom are combined to form a 4- to 6-membered ring;
- or optionally, two Ra substituents on adjacent ring members are combined to form a 5- or 6-membered ring having 0, 1 or 2 ring members selected from O, N and S;
- each Rb is independently selected from the group consisting of halo, CN, hydroxyl, C1-C4 alkyl, C1-C4 deuteroalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C6 cycloalkyl, —NRb1Rb2, —CORb1, —CO2Rb1, —SO2Rb1, —SO2NRb1Rb2, and a 5- or 6-membered heteroaryl which is optionally substituted with C1-C4 alkyl, and wherein each Rb1 and Rb2 is independently selected from the group consisting of H and C1-C4 alkyl or optionally Rb1 and Rb2 when attached to a nitrogen atom are combined to form a 4- to 6-membered ring;
- or optionally, two Rb substituents on adjacent ring members are combined to form a 5- or 6-membered ring having 0, 1 or 2 ring members selected from O, N and S.
A method for preparing a compound having the formula:
- or a pharmaceutically acceptable salt thereof,
- the method comprising:
- reacting a compound
- or a salt thereof,
- with a compound
- to produce the compound
- or a pharmaceutically acceptable salt thereof.
A method for preparing a compound having the formula:
- the method comprising:
- reacting a compound
- with sodium periodate to produce a compound
- reacting the compound
- with lithium diisopropylamide (LDA) followed by N-Fluorobenzenesulfonimide (NFSI) to produce a compound
- reacting the compound
- with iodomethane to produce a compound
- and
- reacting the compound
- with n-Butyllithium to produce the compound
A compound or a salt thereof selected from the group consisting of:
- or a salt thereof.
Dependencies are inferred from the claim text.